// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

OBESITY PHENOTYPES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

L. Kondrateva - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

PARTICIPATION OF UNDERGRADUATE MEDICAL STUDENTS AS INVESTIGATORS IN A RHEUMATOLOGIC COHORT: IMPACT ON DEPRESSION, ANXIETY & STRESS SCALE

S. Basualto - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

Hydroxychloroquine

PREDICTORS OF FLARE IN SLE PATIENTS ATTAINING LUPUS LOW DISEASE ACTIVITY STATE: A REAL-LIFE COHORT STUDY OF 292 PATIENTS WITH 36-MONTH FOLLOW-UP

A. R. Cunha - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

PREDICTORS OF TOXICITY WITH HYDROXYCHLOROQUINE AND CHLOROQUINE USE: A SYSTEMATIC REVIEW

N. Citeroni - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

PREFERENCES FOR TREATMENTS TO PREVENT RHEUMATOID ARTHRITIS: DISCRETE CHOICE SURVEY OF GENERAL POPULATIONS IN UNITED KINGDOM, GERMANY, AND ROMANIA

G. Simons - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

PREVALENCE OF OCULAR DISEASES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY HOSPITAL IN TAIWAN

J. H. Kao - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

QUANTITATIVE AUTOFLUORESCENCE FINDINGS IN PATIENTS UNDERGOING HYDROXYCHLOROQUINE TREATMENT

S. Parrulli - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal insufficiency

Hydroxychloroquine

REACTIVE ARTHRITIS IN SYPHILIS MIMICKING RHEUMATOID ARTHRITIS: A CASE REPORT

S. M. Lao - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Rheumatoid arthritis

Hydroxychloroquine

REAL WORLD POPULATION-BASED ASSESSMENT OF COVID-19 OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS USING BIOLOGIC OR SYNTHETIC DMARDs

L. Wegrzyn - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

REAL-WORLD RETENTION OF JAK INHIBITORS IS LONGER THAN BDMARDS IN RHEUMATOID ARTHRITIS

K. Machlab - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE: PREVALENCE AND DRUG PRESCRIPTIONS IN GERMAN CLAIMS DATA

K. Albrecht - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

Hydroxychloroquine

RISK OF QT INTERVAL PROLONGATION ASSOCIATED WITH CHRONIC USE OF HYDROXYCHLOROQUINE IN RHEUMATIC PATIENTS AND THE EFFECT OF COTREATMENTS

M. Antivalle - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

G. Tarasova - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

SLE PREGNANCIES AT HIGH RISK FOR PRE-ECLAMPSIA BENEFIT MOST FROM COMBINATION OF LOW DOSE ASPIRIN AND HYDROXYCHLOROQUINE

I. Haase - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

Hydroxychloroquine

SURVIVAL ANALYSIS OF TIME TO FIRST ADVERSE DRUG REACTION AND DRUG SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH METHOTREXATE AND HYDROXYCHLOROQUINE MONOTHERAPIES OR COMBINATION THERAPY

K. Velthuis - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

THE IMPACT OF HYDROXYCHLOROQUINE DAILY DOSE IN THE PREVENTION OF FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN REMISSION

S. Fasano - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

THE PREVALENCE AND RISK FACTORS OF RETINAL TOXICITY ASSOCIATED WITH LONG-TERM HYDROXYCHLOROQUINE USE

S. Do - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

TOLERABILITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, PRELIMINARY RESULTS

G. Tarasova - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

TREATMENT OF INTERSTITIAL LUNG INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: EXPERIENCE IN A THIRD LEVEL HOSPITAL

I. Gonzlez Fernndez - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

UNMET TREATMENT NEEDS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A CROSS-SECTIONAL ASSESSMENT OF DISEASE ACTIVITY IN SLE PATIENTS DURING THEIR LAST VISIT

O. Gioti - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved